Aura Biosciences To Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan For The First-Line Treatment Of Patients With Early-Stage Choroidal Melanoma At AAO 2023
Portfolio Pulse from Benzinga Newsdesk
Aura Biosciences Inc. (NASDAQ:AURA) announced that updated data from the Phase 2 trial evaluating the safety and efficacy of its first virus-like drug conjugate (VDC) product candidate, bel-sar, for the first-line treatment of adult patients with early-stage choroidal melanoma will be presented at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting. The meeting will be held from November 3-6, 2023, in San Francisco.
October 31, 2023 | 8:44 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Aura Biosciences is set to present updated data from a Phase 2 trial of its drug candidate, bel-sar, at the AAO 2023 Annual Meeting. This could potentially impact the company's stock depending on the results presented.
The presentation of updated Phase 2 trial data is a significant event for Aura Biosciences. Positive results could boost investor confidence and potentially lead to an increase in the company's stock price. However, without knowing the results, the impact on the stock price remains uncertain.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100